{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:23:58Z","timestamp":1791404638796,"version":"4.3.3"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"7331","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1038\/nature09657","type":"journal-article","created":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T09:28:40Z","timestamp":1295947720000},"page":"483-490","source":"Crossref","is-referenced-by-count":904,"title":["The challenge of new drug discovery for tuberculosis"],"prefix":"10.1038","volume":"469","author":[{"given":"Anil","family":"Koul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Arnoult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nacer","family":"Lounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Guillemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Andries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,26]]},"reference":[{"key":"BFnature09657_CR1","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1185449","volume":"328","author":"C Dye","year":"2010","unstructured":"Dye, C. & Williams, B. G. The population dynamics and control of tuberculosis. Science 328, 856\u2013861 (2010)","journal-title":"Science"},{"key":"BFnature09657_CR2","first-page":"931","volume":"76","author":"RL Riley","year":"1957","unstructured":"Riley, R. L. Aerial dissemination of pulmonary tuberculosis. Am. Rev. Tuberc. 76, 931\u2013941 (1957)","journal-title":"Am. Rev. Tuberc."},{"key":"BFnature09657_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nrmicro2236","volume":"7","author":"CE Barry III","year":"2009","unstructured":"Barry, C. E., III et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Rev. Microbiol. 7, 845\u2013855 (2009)","journal-title":"Nature Rev. Microbiol."},{"key":"BFnature09657_CR4","unstructured":"World Health Organization. Multidrug and Extensive Drug Resistant Tuberculosis: 2010 Global Report on Surveillance and Response (World health Organization, 2010)"},{"key":"BFnature09657_CR5","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/S0140-6736(10)60410-2","volume":"375","author":"NR Gandhi","year":"2010","unstructured":"Gandhi, N. R. et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375, 1830\u20131843 (2010)","journal-title":"Lancet"},{"key":"BFnature09657_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1056\/NEJMoa022928","volume":"348","author":"C Mitnick","year":"2003","unstructured":"Mitnick, C. et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N. Engl. J. Med. 348, 119\u2013128 (2003)","journal-title":"N. Engl. J. Med."},{"key":"BFnature09657_CR7","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(10)60359-9","volume":"375","author":"Z Ma","year":"2010","unstructured":"Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J. & Wang, X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 375, 2100\u20132109 (2010)","journal-title":"Lancet"},{"key":"BFnature09657_CR8","unstructured":"World Health Organization. The Global Plan to Stop TB 2011\u20132015: Transforming the Fight Towards Elimination of Tuberculosis (World Health Organization, 2010)"},{"key":"BFnature09657_CR9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"M Niemi","year":"2003","unstructured":"Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J. & Kivisto, K. T. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42, 819\u2013850 (2003)","journal-title":"Clin. Pharmacokinet."},{"key":"BFnature09657_CR10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/QAD.0b013e328329148e","volume":"23","author":"RF L\u2019homme","year":"2009","unstructured":"L\u2019homme, R. F. et al. Clinical experience with the combined use of lopinavir\/ritonavir and rifampicin. AIDS 23, 863\u2013865 (2009)","journal-title":"AIDS"},{"key":"BFnature09657_CR11","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/jac\/dkp263","volume":"64","author":"H Khachi","year":"2009","unstructured":"Khachi, H., O\u2019Connell, R., Ladenheim, D. & Orkin, C. Pharmacokinetic interactions between rifabutin and lopinavir\/ritonavir in HIV-infected patients with mycobacterial co-infection. J. Antimicrob. Chemother. 64, 871\u2013873 (2009)","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnature09657_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1124\/mol.56.6.1329","volume":"56","author":"B Goodwin","year":"1999","unstructured":"Goodwin, B., Hodgson, E. & Liddle, C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329\u20131339 (1999)","journal-title":"Mol. Pharmacol."},{"key":"BFnature09657_CR13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","volume":"104","author":"EA Campbell","year":"2001","unstructured":"Campbell, E. A. et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104, 901\u2013912 (2001)","journal-title":"Cell"},{"key":"BFnature09657_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1086\/515174","volume":"28","author":"WJ Burman","year":"1999","unstructured":"Burman, W. J., Gallicano, K. & Peloquin, C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin. Infect. Dis. 28, 419\u2013429 (1999)","journal-title":"Clin. Infect. Dis."},{"key":"BFnature09657_CR15","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0761-8425(07)91389-3","volume":"24","author":"NO Tour\u00e9","year":"2007","unstructured":"Tour\u00e9, N. O. et al. Tuberculosis and diabetes [in French with English abstract]. Rev. Mal. Respir. 24, 869\u2013875 (2007)","journal-title":"Rev. Mal. Respir."},{"key":"BFnature09657_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1473-3099(09)70282-8","volume":"9","author":"KE Dooley","year":"2009","unstructured":"Dooley, K. E. & Chaisson, R. E. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect. Dis. 9, 737\u2013746 (2009)","journal-title":"Lancet Infect. Dis."},{"key":"BFnature09657_CR17","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1128\/AAC.00447-09","volume":"54","author":"R Ruslami","year":"2010","unstructured":"Ruslami, R. et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob. Agents Chemother. 54, 1068\u20131074 (2010)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature09657_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd2201","volume":"6","author":"DJ Payne","year":"2007","unstructured":"Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29\u201340 (2007)An excellent review on what is ailing antibacterial research and remedial measures to be taken.","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnature09657_CR19","volume-title":"Chemical Properties of Antibacterial Drugs","author":"M Macielag","year":"2005","unstructured":"Macielag, M. Chemical Properties of Antibacterial Drugs (45th Interscience Conference for Antimicrobial Agents and Chemotherapy (ICAAC), December 16\u201319, 2005)"},{"key":"BFnature09657_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/31159","volume":"393","author":"ST Cole","year":"1998","unstructured":"Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537\u2013544 (1998)A landmark paper describing the genomic sequence of  M. tuberculosis  and thereby identifying several new drug targets.","journal-title":"Nature"},{"key":"BFnature09657_CR21","unstructured":"Working Group on New TB Drugs The global TB drug pipeline. \u3008\n                    http:\/\/www.newtbdrugs.org\/project.php?id=183\n                    \n                  \u3009 (2010)"},{"key":"BFnature09657_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/ncomms1060","volume":"1","author":"K Pethe","year":"2010","unstructured":"Pethe, K. et al. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nature Commun. 1, 57 (2010)","journal-title":"Nature Commun."},{"key":"BFnature09657_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis . Science 307, 223\u2013227 (2005)Describes the discovery of the novel drug candidate TMC207.","journal-title":"Science"},{"key":"BFnature09657_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nchembio884","volume":"3","author":"A Koul","year":"2007","unstructured":"Koul, A. et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chem. Biol. 3, 323\u2013324 (2007)","journal-title":"Nature Chem. Biol."},{"key":"BFnature09657_CR25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.1171583","volume":"324","author":"V Makarov","year":"2009","unstructured":"Makarov, V. et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801\u2013804 (2009)","journal-title":"Science"},{"key":"BFnature09657_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1574-6968.2010.01959.x","volume":"308","author":"D Bald","year":"2010","unstructured":"Bald, D. & Koul, A. Respiratory ATP synthesis: the new generation of mycobacterial drug targets? FEMS Microbiol. Lett. 308, 1\u20137 (2010)","journal-title":"FEMS Microbiol. Lett."},{"key":"BFnature09657_CR27","doi-asserted-by":"publisher","first-page":"25273","DOI":"10.1074\/jbc.M803899200","volume":"283","author":"A Koul","year":"2008","unstructured":"Koul, A. et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283, 25273\u201325280 (2008)","journal-title":"J. Biol. Chem."},{"key":"BFnature09657_CR28","doi-asserted-by":"publisher","first-page":"11945","DOI":"10.1073\/pnas.0711697105","volume":"105","author":"SP Rao","year":"2008","unstructured":"Rao, S. P., Alonso, S., Rand, L., Dick, T. & Pethe, K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis . Proc. Natl Acad. Sci. USA 105, 11945\u201311950 (2008)Important research demonstrating the effect of inhibition of the respiratory chain for killing dormant TB bacilli.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature09657_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nrmicro1065","volume":"3","author":"HI Boshoff","year":"2005","unstructured":"Boshoff, H. I. & Barry, C. E., III Tuberculosis\u2014metabolism and respiration in the absence of growth. Nature Rev. Microbiol. 3, 70\u201380 (2005)This review provides an excellent understanding of how tuberculosis adapts and survives during long-term persistence.","journal-title":"Nature Rev. Microbiol."},{"key":"BFnature09657_CR30","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1126\/science.1176667","volume":"325","author":"MA Fischbach","year":"2009","unstructured":"Fischbach, M. A. & Walsh, C. T. Antibiotics for emerging pathogens. Science 325, 1089\u20131093 (2009)","journal-title":"Science"},{"key":"BFnature09657_CR31","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1128\/AAC.01182-08","volume":"53","author":"KN Williams","year":"2009","unstructured":"Williams, K. N. et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53, 1314\u20131319 (2009)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature09657_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/jac\/dki148","volume":"56","author":"J Fort\u00fan","year":"2005","unstructured":"Fort\u00fan, J. et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56, 180\u2013185 (2005)","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnature09657_CR33","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","volume":"46","author":"JE Conte Jr","year":"2002","unstructured":"Conte, J. E., Jr, Golden, J. A., Kipps, J. & Zurlinden, E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. 46, 1475\u20131480 (2002)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature09657_CR34","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1126\/science.1164571","volume":"322","author":"R Singh","year":"2008","unstructured":"Singh, R. et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322, 1392\u20131395 (2008)","journal-title":"Science"},{"key":"BFnature09657_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4161\/cib.2.3.7926","volume":"2","author":"U Manjunatha","year":"2009","unstructured":"Manjunatha, U., Boshoff, H. I. & Barry, C. E. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun. Integr. Biol. 2, 215\u2013218 (2009)","journal-title":"Commun. Integr. Biol."},{"key":"BFnature09657_CR36","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1128\/AAC.39.12.2620","volume":"39","author":"HF Chambers","year":"1995","unstructured":"Chambers, H. F. et al. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob. Agents Chemother. 39, 2620\u20132624 (1995)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature09657_CR37","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1126\/science.1167498","volume":"323","author":"JE Hugonnet","year":"2009","unstructured":"Hugonnet, J. E., Tremblay, L. W., Boshoff, H. I., Barry, C. E., III & Blanchard, J. S. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis . Science 323, 1215\u20131218 (2009)Renewed interest in \u03b2-lactams and their combination with broad-spectrum lactamase inhibitors for TB treatment.","journal-title":"Science"},{"key":"BFnature09657_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/CMR.00037-09","volume":"23","author":"SM Drawz","year":"2010","unstructured":"Drawz, S. M. & Bonomo, R. A. Three decades of \u03b2-lactamase inhibitors. Clin. Microbiol. Rev. 23, 160\u2013201 (2010)","journal-title":"Clin. Microbiol. Rev."},{"key":"BFnature09657_CR39","first-page":"79","volume":"13","author":"D Agrawal","year":"2009","unstructured":"Agrawal, D., Udwadia, Z. F., Rodriguez, C. & Mehta, A. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int. J. Tuberc. Lung Dis. 13, 79\u201383 (2009)","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"BFnature09657_CR40","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1021\/jm700967e","volume":"51","author":"R O\u2019Shea","year":"2008","unstructured":"O\u2019Shea, R. & Moser, H. E. Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem. 51, 2871\u20132878 (2008)A thorough study of the physicochemical properties of antibacterial compounds and accompanying chemical space.","journal-title":"J. Med. Chem."},{"key":"BFnature09657_CR41","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1021\/ci800429e","volume":"49","author":"TJ Ritchie","year":"2009","unstructured":"Ritchie, T. J., Luscombe, C. N. & Macdonald, S. J. Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet? J. Chem. Inf. Model. 49, 1025\u20131032 (2009)","journal-title":"J. Chem. Inf. Model."},{"key":"BFnature09657_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1128\/MMBR.00028-07","volume":"72","author":"EC Hett","year":"2008","unstructured":"Hett, E. C. & Rubin, E. J. Bacterial growth and cell division: a mycobacterial perspective. Microbiol. Mol. Biol. Rev. 72, 126\u201356 (2008)","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"BFnature09657_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nrmicro840","volume":"2","author":"A Koul","year":"2004","unstructured":"Koul, A., Herget, T., Klebl, B. & Ullrich, A. Interplay between mycobacteria and host signalling pathways. Nature Rev. Microbiol. 2, 189\u2013202 (2004)","journal-title":"Nature Rev. Microbiol."},{"key":"BFnature09657_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.imlet.2007.12.005","volume":"116","author":"R Sz\u00e9kely","year":"2008","unstructured":"Sz\u00e9kely, R. et al. A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling. Immunol. Lett. 116, 225\u2013231 (2008)","journal-title":"Immunol. Lett."},{"key":"BFnature09657_CR45","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1073\/pnas.0811275106","volume":"106","author":"JR Miller","year":"2009","unstructured":"Miller, J. R. et al. A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc. Natl Acad. Sci. USA 106, 1737\u20131742 (2009)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature09657_CR46","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1126\/science.1099384","volume":"304","author":"A Walburger","year":"2004","unstructured":"Walburger, A. et al. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science 304, 1800\u20131804 (2004)","journal-title":"Science"},{"key":"BFnature09657_CR47","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1073\/pnas.0909133107","volume":"107","author":"B Zhou","year":"2010","unstructured":"Zhou, B. et al. Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents. Proc. Natl Acad. Sci. USA 107, 4573\u20134578 (2010)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature09657_CR48","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cell.2010.02.012","volume":"140","author":"D Kumar","year":"2010","unstructured":"Kumar, D. et al. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis . Cell 140, 731\u2013743 (2010)","journal-title":"Cell"},{"key":"BFnature09657_CR49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1365-2958.2005.04524.x","volume":"56","author":"LA Keating","year":"2005","unstructured":"Keating, L. A. et al. The pyruvate requirement of some members of the Mycobacterium tuberculosis complex is due to an inactive pyruvate kinase: implications for in vivo growth. Mol. Microbiol. 56, 163\u2013174 (2005)","journal-title":"Mol. Microbiol."},{"key":"BFnature09657_CR50","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1128\/AAC.00934-10","volume":"54","author":"K Andries","year":"2010","unstructured":"Andries, K., Gevers, T. & Lounis, N. Bactericidal potencies of new regimens are not predictive for their sterilizing potencies in a murine model of tuberculosis. Antimicrob. Agents Chemother. 54, 4540\u20134544 (2010)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature09657_CR51","doi-asserted-by":"publisher","first-page":"12275","DOI":"10.1073\/pnas.1003219107","volume":"107","author":"N Dhar","year":"2010","unstructured":"Dhar, N. & McKinney, J. D. Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice. Proc. Natl Acad. Sci. USA 107, 12275\u201312280 (2010)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature09657_CR52","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1164\/rccm.200807-1152OC","volume":"180","author":"M Ibrahim","year":"2009","unstructured":"Ibrahim, M., Truffot-Pernot, C., Andries, K., Jarlier, V. & Veziris, N. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am. J. Respir. Crit. Care Med. 180, 553\u2013557 (2009)","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnature09657_CR53","first-page":"346","volume":"56","author":"WH Feldman","year":"1947","unstructured":"Feldman, W. H., Karlson, A. G. & Hinshaw, H. C. Streptomycin in experimental tuberculosis: the effects in guinea pigs following infection in intravenous inoculation. Am. Rev. Tuberc. 56, 346\u2013359 (1947)","journal-title":"Am. Rev. Tuberc."},{"key":"BFnature09657_CR54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2008.11.014","volume":"136","author":"JM Davis","year":"2009","unstructured":"Davis, J. M. & Ramakrishnan, L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 136, 37\u201349 (2009)","journal-title":"Cell"},{"key":"BFnature09657_CR55","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1126\/science.1184784","volume":"328","author":"DG Russell","year":"2010","unstructured":"Russell, D. G., Barry, C. E., III & Flynn, J. L. Tuberculosis: what we don\u2019t know can, and does, hurt us. Science 328, 852\u2013856 (2010)","journal-title":"Science"},{"key":"BFnature09657_CR56","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/S1472-9792(08)70038-6","volume":"88","author":"PR Donald","year":"2008","unstructured":"Donald, P. R. & Diacon, A. H. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb.) 88 (suppl. 1). S75\u2013S83 (2008)","journal-title":"Tuberculosis (Edinb.)"},{"key":"BFnature09657_CR57","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1128\/AAC.01204-07","volume":"52","author":"R Rustomjee","year":"2008","unstructured":"Rustomjee, R. et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52, 2831\u20132835 (2008)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature09657_CR58","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1473-3099(10)70003-7","volume":"10","author":"RS Wallis","year":"2010","unstructured":"Wallis, R. S. et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect. Dis. 10, 68\u201369 (2010)","journal-title":"Lancet Infect. Dis."},{"key":"BFnature09657_CR59","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1164\/ajrccm\/147.4.1062","volume":"147","author":"DA Mitchison","year":"1993","unstructured":"Mitchison, D. A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am. Rev. Respir. Dis. 147, 1062\u20131063 (1993)An interesting demonstration of using 2-months culture conversion as a surrogate marker in TB trials.","journal-title":"Am. Rev. Respir. Dis."},{"key":"BFnature09657_CR60","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/S0140-6736(10)60359-5","volume":"375","author":"RS Wallis","year":"2010","unstructured":"Wallis, R. S. et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375, 1920\u20131937 (2010)An excellent review on the need for biomarkers and other tools for shortening TB trials.","journal-title":"Lancet"},{"key":"BFnature09657_CR61","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","volume":"360","author":"AH Diacon","year":"2009","unstructured":"Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360, 2397\u20132405 (2009)","journal-title":"N. Engl. J. Med."},{"key":"BFnature09657_CR62","first-page":"128","volume":"12","author":"R Rustomjee","year":"2008","unstructured":"Rustomjee, R. et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12, 128\u2013138 (2008)","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"BFnature09657_CR63","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09247","volume":"466","author":"MP Berry","year":"2010","unstructured":"Berry, M. P. et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973\u2013977 (2010)","journal-title":"Nature"},{"key":"BFnature09657_CR64","first-page":"663","volume":"14","author":"M Spigelman","year":"2010","unstructured":"Spigelman, M., Woosley, R. & Gheuens, J. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int. J. Tuberc. Lung Dis. 14, 663\u2013664 (2010)","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"BFnature09657_CR65","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.chom.2008.05.006","volume":"3","author":"J Pieters","year":"2008","unstructured":"Pieters, J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe 3, 399\u2013407 (2008)","journal-title":"Cell Host Microbe"},{"key":"BFnature09657_CR66","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.mib.2006.12.007","volume":"10","author":"N Dhar","year":"2007","unstructured":"Dhar, N. & McKinney, J. D. Microbial phenotypic heterogeneity and antibiotic tolerance. Curr. Opin. Microbiol. 10, 30\u201338 (2007)","journal-title":"Curr. Opin. Microbiol."},{"key":"BFnature09657_CR67","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1086\/651489","volume":"50","author":"B Beresford","year":"2010","unstructured":"Beresford, B. & Sadoff, J. C. Update on research and development pipeline: tuberculosis vaccines. Clin. Infect. Dis. 50 (suppl. 3). S178\u2013S183 (2010)","journal-title":"Clin. Infect. Dis."},{"key":"BFnature09657_CR68","doi-asserted-by":"publisher","first-page":"15629","DOI":"10.1073\/pnas.0507850102","volume":"102","author":"L Shi","year":"2005","unstructured":"Shi, L. et al. Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc. Natl Acad. Sci. USA 102, 15629\u201315634 (2005)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature09657_CR69","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1073\/pnas.0500469102","volume":"102","author":"EA Weinstein","year":"2005","unstructured":"Weinstein, E. A. et al. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc. Natl Acad. Sci. USA 102, 4548\u20134553 (2005)An interesting demonstration of targeting NADH dehydrogenase for identifying new TB drugs or re-purposing old drug classes.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature09657_CR70","unstructured":"MOE. v. 2009. 10 \u3008\n                    http:\/\/www.chemcomp.com\n                    \n                  \u3009 (Chemical Computing Group Inc Montreal, Canada) (2010)"},{"key":"BFnature09657_CR71","unstructured":"SIMCA-P+12. \u3008\n                    http:\/\/www.umetrics.com\n                    \n                  \u3009 (Umetrics AB, Ume\u00e5, Sweden) (2010)"},{"key":"BFnature09657_CR72","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1016\/j.bmc.2008.03.020","volume":"16","author":"S Hirano","year":"2008","unstructured":"Hirano, S., Ichikawa, S. & Matsuda, A. Structure\u2013activity relationship of truncated analogs of caprazamycins as potential anti-tuberculosis agents. Bioorg. Med. Chem. 16, 5123\u20135133 (2008)","journal-title":"Bioorg. Med. Chem."},{"key":"BFnature09657_CR73","unstructured":"Hennessy, A. et. al. Substituted (Aza)-1 methyl -1H-Quinolin-2-ones as antibacterials. Patent W02010\/046388A1. (2010)"},{"key":"BFnature09657_CR74","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.micro.112408.134043","volume":"64","author":"MC Chao","year":"2010","unstructured":"Chao, M. C. & Rubin, E. J. Letting sleeping dos lie: does dormancy play a role in tuberculosis? Annu. Rev. Microbiol. 64, 293\u2013311 (2010)","journal-title":"Annu. Rev. Microbiol."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature09657.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature09657","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature09657.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:49:11Z","timestamp":1684417751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature09657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":74,"journal-issue":{"issue":"7331","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["BFnature09657"],"URL":"https:\/\/doi.org\/10.1038\/nature09657","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}